Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis.
Wang, Jie Chen, Hongyu Tang, Zihuan Zhang, Jinquan Xu, Yuanwei Wan, Ke Hussain, Kifah Gkoutos, Georgios V Han, Yuchi Chen, Yucheng
Wang, Jie
Chen, Hongyu
Tang, Zihuan
Zhang, Jinquan
Xu, Yuanwei
Wan, Ke
Hussain, Kifah
Gkoutos, Georgios V
Han, Yuchi
Chen, Yucheng
Abstract
Fifteen studies comprising 2765 patients (mean age 75.9 ± 9.3 years; 83.7% male) with a mean follow-up duration of 18.7 ± 17.1 months were included in the meta-analysis. There was a decrease in left ventricular ejection fraction (LVEF) (standard mean differences (SMD: -0.17; 95% confidence interval (CI), -0.31 to -0.03; P = 0.02) but were no significant differences in intraventricular septum (IVS) thickness or global longitudinal strain (GLS) after tafamidis treatment. However, subgroup analysis showed no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment (SMD: -0.11; 95% CI, -0.34 to 0.12, P = 0.34). In addition, the group with tafamidis treatment had a decreased risk for all-cause death or heart transplantation compared to patients without treatment (the pooled RR, 0.44; 95% CI, 0.31-0.65; P < 0.01). Subgroup analysis showed that there was no significant difference of tafamidis on the outcomes in patients with wild-type or hereditary ATTR (RR, 0.44; 95% CI, 0.27-0.73 versus 0.21, 95% CI, 0.11-0.40, P = 0.08). Furthermore, tafamidis treatment was associated with a lower risk of the composite endpoint (RR, 0.57; 95% CI, 0.42-0.77; P < 0.01).
MIDER Authors
Citations
Altmetric:
Date
2023-08-24
Type
Article
Subject
Cardiology, Health services. Management
Collections
Citation
Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, Hussain K, Gkoutos GV, Han Y, Chen Y. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023 Aug 24;63:102172. doi: 10.1016/j.eclinm.2023.102172. PMID: 37662524; PMCID: PMC10474377.
Journal / Source Title
EClinicalMedicine
DOI
10.1016/j.eclinm.2023.102172
PMID
37662524
Publisher
Elsevier
Publisher’s URL
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00349-8/fulltext